{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+for+nirmatrelvir", "query": { "intervention": "placebo for nirmatrelvir" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-29T08:21:32.301Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05047601", "title": "A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "PF-07321332", "type": "DRUG" }, { "name": "Placebo for PF-07321332", "type": "DRUG" }, { "name": "Placebo for Ritonavir", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2954, "start_date": "2021-09-09", "completion_date": "2022-04-12", "has_results": true, "last_update_posted_date": "2023-05-06", "last_synced_at": "2026-09-29T08:21:32.301Z", "location_count": 64, "location_summary": "Pelham, Alabama • Tucson, Arizona • Fullerton, California + 36 more", "locations": [ { "city": "Pelham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Bradenton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05047601" }, { "nct_id": "NCT05567952", "title": "A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "nirmatrelvir", "type": "DRUG" }, { "name": "ritonavir", "type": "DRUG" }, { "name": "placebo for nirmatrelvir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 436, "start_date": "2022-10-19", "completion_date": "2024-02-09", "has_results": true, "last_update_posted_date": "2024-10-08", "last_synced_at": "2026-09-29T08:21:32.301Z", "location_count": 67, "location_summary": "Mesa, Arizona • Phoenix, Arizona • Surprise, Arizona + 47 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Surprise", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Canoga Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05567952" }, { "nct_id": "NCT05011513", "title": "Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "PF-07321332", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1440, "start_date": "2021-08-25", "completion_date": "2022-07-25", "has_results": true, "last_update_posted_date": "2023-08-14", "last_synced_at": "2026-09-29T08:21:32.301Z", "location_count": 78, "location_summary": "Pelham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 51 more", "locations": [ { "city": "Pelham", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Canoga Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05011513" }, { "nct_id": "NCT05576662", "title": "Paxlovid for Treatment of Long Covid", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Post-acute Sequelae of SARS-CoV-2 Infection", "Long COVID" ], "interventions": [ { "name": "Nirmatrelvir", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 168, "start_date": "2022-11-08", "completion_date": "2023-09-12", "has_results": true, "last_update_posted_date": "2025-09-04", "last_synced_at": "2026-09-29T08:21:32.301Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05576662" }, { "nct_id": "NCT07597902", "title": "SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Post-acute Sequelae of COVID-19", "Long COVID" ], "interventions": [ { "name": "Valacyclovir", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" }, { "name": "Paxlovid", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 150, "start_date": "2026-06-01", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-09-29T08:21:32.301Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07597902" }, { "nct_id": "NCT05595369", "title": "RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Long COVID", "Long Covid19" ], "interventions": [ { "name": "Experimental: Paxlovid 25 day dosing", "type": "DRUG" }, { "name": "Experimental: Paxlovid 15 day dosing", "type": "DRUG" }, { "name": "Placebo Comparator: Control", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kanecia Obie Zimmerman", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 963, "start_date": "2023-07-26", "completion_date": "2025-03-13", "has_results": true, "last_update_posted_date": "2025-12-02", "last_synced_at": "2026-09-29T08:21:32.301Z", "location_count": 68, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05595369" }, { "nct_id": "NCT05438602", "title": "A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Nirmatrelvir", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Placebo for nirmatrelvir", "type": "DRUG" }, { "name": "Placebo for ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 158, "start_date": "2022-08-03", "completion_date": "2023-11-13", "has_results": true, "last_update_posted_date": "2024-09-23", "last_synced_at": "2026-09-29T08:21:32.301Z", "location_count": 25, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Doral, Florida + 15 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Doral", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05438602" }, { "nct_id": "NCT05545319", "title": "A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)", "Coronavirus Disease 2019 (COVID-19)", "Immunocompromised", "Hospitalization", "Child, Hospitalized" ], "interventions": [ { "name": "Nirmatrelvir", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Placebo for nirmatrelvir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 0, "start_date": "2022-12-13", "completion_date": "2024-01-06", "has_results": false, "last_update_posted_date": "2023-03-01", "last_synced_at": "2026-09-29T08:21:32.301Z", "location_count": 2, "location_summary": "Cooperstown, New York • New York, New York", "locations": [ { "city": "Cooperstown", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05545319" }, { "nct_id": "NCT05965726", "title": "RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Long COVID-19", "Long COVID" ], "interventions": [ { "name": "Paxlovid", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Nirmatrelvir-matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kanecia Obie Zimmerman", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 964, "start_date": "2023-07-26", "completion_date": "2025-03-13", "has_results": true, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-09-29T08:21:32.301Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05965726" }, { "nct_id": "NCT05668091", "title": "A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Long COVID" ], "interventions": [ { "name": "Nirmatrelvir", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Harlan M Krumholz", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2023-04-14", "completion_date": "2024-08-21", "has_results": false, "last_update_posted_date": "2024-12-02", "last_synced_at": "2026-09-29T08:21:32.301Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05668091" } ] }